Metronidazole combined with nystatin (vagitories) in the prevention of bacterial vaginosis after initial treatment with oral metronidazole.
In a double-blind trial comprising 66 patients we assessed the effect of metronidazole-nystatin vagitories on the prevention of bacterial vaginosis (BV) in women using IUD as a contraceptive method after an initial oral single dose of 2.0 g metronidazole and 7 days of intravaginal metronidazole-nystatin or placebo treatment. The prophylactic treatment consisted of metronidazole-nystatin or placebo vagitories applied at bedtime for 3 days after menstruation over 6 consecutive menstrual periods. The patients were randomized in two study groups: a treatment group of 32 patients (group A) and a placebo group of 34 patients (group B). The overall objective cure rate after the initial treatment was 97% in group A and 91% in group B. After 6 months of follow-up, the overall cumulative objective cure rate in group A was 100%, and 76% in group B. The single-dose oral treatment was well tolerated and no notable side effects were recorded.
Pulkkinen
P
P
Department of Obstetrics and Gynecology, Tampere University, Finland.
Saranen
M
M
Kaaja
R
R
D000282:Administration, Intravaginal; D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007434:Intrauterine Devices / Q000009:adverse effects*; D008795:Metronidazole / Q000008:administration & dosage*; D009761:Nystatin / Q000008:administration & dosage*; D016896:Treatment Outcome; D016585:Vaginosis, Bacterial / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control
D004338:Drug Combinations; D009761:Nystatin; D008795:Metronidazole